Phenomic

Phenomic’s mission is to raise the survival curve for the hardest to treat solid tumors (e.g., colorectal, pancreatic, breast cancers). We believe the reason why drugs for these cancers have not translated well in the clinic historically is that they were largely discovered and studied in models that do not account for the diversity of cell types present in human tumors. To address this challenge, we have built an ML-powered transcriptomics platform that allows us to understand the interactions of all the cell types in these tumors to identify compelling targets and a system to test our drugs in human tumor explants thus delivering translational insights during our discovery process. Our lead program is a CD3 engager that uses a novel targeting approach identified by our platform that should be able to overcome limitations of traditional tumor-associated antigens. This program is generating compelling results in challenging cancers and is now at a development candidate stage demonstrating Phenomic’s ability to identify novel high-impact, druggable targets.